| scholarly article | Q13442814 |
| P50 | author | Myron R. Melamed | Q108424692 |
| Lloyd J. Old | Q1866929 | ||
| P2093 | author name string | Mendelsohn J | |
| Rettig WJ | |||
| Real FX | |||
| Chesa PG | |||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 4726-4731 | |
| P577 | publication date | 1986-09-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation | |
| P478 | volume | 46 |
| Q35093992 | A phase II study of gefitinib in patients with metastatic melanoma |
| Q33563932 | Activation of EGFR on monocytes is required for human cytomegalovirus entry and mediates cellular motility |
| Q34635622 | Activity of a recombinant fusion protein between transforming growth factor type alpha and Pseudomonas toxin |
| Q36585770 | Affibody modified and radiolabeled gold-iron oxide hetero-nanostructures for tumor PET, optical and MR imaging |
| Q38748970 | Antiangiogenic antibody improves melanoma detection by fluorescently labeled therapeutic antibodies |
| Q37253567 | Antigens of melanocytes and melanoma |
| Q39865068 | Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo |
| Q35816141 | Cell surface molecules of human melanoma. Immunohistochemical analysis of the gp57, GD3, and mel-CSPG antigenic systems |
| Q41723660 | Different regulation of mid-size neurofilament and N-myc mRNA expression during neuroblastoma cell differentiation induced by retinoic acid |
| Q34442002 | Dual inhibition of epidermal growth factor receptor and insulin‐like growth factor receptor I: Reduction of angiogenesis and tumor growth in cutaneous squamous cell carcinoma |
| Q37434706 | Epidermal Growth Factor Receptor Silencing Blunts the Slow Force Response to Myocardial Stretch |
| Q38764557 | Epidermal growth factor is a critical regulator of the cytokine IL-33 in intestinal epithelial cells. |
| Q40146714 | Epidermal growth factor receptor is not required for human cytomegalovirus entry or signaling |
| Q35229908 | Epidermal growth factor receptor plays an anabolic role in bone metabolism in vivo |
| Q55252435 | Ex vivo delivery of suicide genes into melanoma cells using epidermal growth factor receptor-specific Fab immunogene. |
| Q34382777 | Exploiting novel molecular targets in gastrointestinal cancers. |
| Q38995370 | Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway |
| Q43744071 | Expression of epidermal growth factor in the rat kidney. An immunocytochemical and in situ hybridization study. |
| Q36467797 | Expression of epidermal growth factor receptor (EGF-R) in non-small cell lung cancer. Use of archival tissue and correlation of EGF-R with histology, tumour size, node status and survival |
| Q69053521 | Expression of epidermal growth factor receptor in benign and malignant primary tumours of the breast |
| Q37708758 | Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer 89Zr-imgatuzumab |
| Q36353103 | Extracellular matrix-modulated expression of human cell surface glycoproteins A42 and J143. Intrinsic and extrinsic signals determine antigenic phenotype |
| Q33732697 | Fortilin binds IRE1α and prevents ER stress from signaling apoptotic cell death |
| Q68453246 | Growth factor binding and bioactivity in human kidney epithelial cell cultures |
| Q37253585 | Growth factors in melanoma |
| Q36232248 | Human cytomegalovirus induction of a unique signalsome during viral entry into monocytes mediates distinct functional changes: a strategy for viral dissemination |
| Q55384914 | Imaging EGFR and HER3 through 89Zr-labeled MEHD7945A (Duligotuzumab). |
| Q41920704 | Immunohistochemical studies on oncogene products (EGF-R, c-erbB-2) and growth factors (EGF, TGF-alpha) in human breast cancer: their relationship to oestrogen receptor status, histological grade, mitotic index and nodal status |
| Q42258990 | Impact of KRAS Mutations on Management of Colorectal Carcinoma |
| Q35803276 | In vitro and in vivo assessment of targeting lipid-based nanoparticles to the epidermal growth factor-receptor (EGFR) using a novel Heptameric ZEGFR domain. |
| Q41503458 | Is EGFR expression altered following postoperative chemotherapy for colorectal adenocarcinoma? |
| Q40998701 | Isolation and characterization of a novel bladder cancer cell line: inhibition by epidermal growth factor. |
| Q27342948 | Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor |
| Q47739142 | Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. |
| Q34473944 | Microscopic lymph node tumor burden quantified by macroscopic dual-tracer molecular imaging |
| Q36845960 | Molecular imaging of hepatocellular carcinoma xenografts with epidermal growth factor receptor targeted affibody probes |
| Q54254744 | Navigating the Host Cell Response during Entry into Sites of Latent Cytomegalovirus Infection. |
| Q33631435 | Nimotuzumab in combination with radiotherapy in high grade glioma patients: a single institution experience |
| Q38787773 | Novel EGFR-targeted strategy with hybrid peptide against oesophageal squamous cell carcinoma. |
| Q34429075 | PET of EGFR expression with an 18F-labeled affibody molecule |
| Q33414773 | Phase I trial to evaluate the tumor and normal tissue uptake, radiation dosimetry and safety of (111)In-DTPA-human epidermal growth factor in patients with metastatic EGFR-positive breast cancer |
| Q36352524 | Phenotypic heterogeneity of melanoma. Relation to the differentiation program of melanoma cells |
| Q37232296 | Prognostic value of epidermal growth factor receptor expression in cervical carcinoma |
| Q41689033 | Quantitative assay of epidermal growth factor receptor in human squamous cell carcinomas of the oral region by an avidin-biotin method |
| Q30436623 | Rational design for multifunctional non-liposomal lipid-based nanocarriers for cancer management: theory to practice. |
| Q27852990 | Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma |
| Q43202361 | Specifically regulated genes in malignant melanoma tissues identified by subtractive hybridization |
| Q41129373 | Tagging staphylococcal enterotoxin B (SEB) with TGFaL3 for breast cancer therapy |
| Q39999288 | Targeted inhibition of tumour cell growth by a bispecific single-chain toxin containing an antibody domain and TGF alpha |
| Q38161358 | Targeted therapy in nonmelanoma skin cancers. |
| Q33959323 | The epidermal growth factor receptor in breast cancer. |
| Q34493341 | The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis |
| Q41522434 | Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma. |
| Q91760373 | Toxoplasma gondii induces prolonged host epidermal growth factor receptor signalling to prevent parasite elimination by autophagy: Perspectives for in vivo control of the parasite |
| Q36356124 | Transformation of human kidney proximal tubule cells by ras-containing retroviruses. Implications for tumor progression |
| Q41760172 | Transformation of murine melanocytes by basic fibroblast growth factor cDNA and oncogenes and selective suppression of the transformed phenotype in a reconstituted cutaneous environment |
| Q68587614 | Two subclasses of EGF receptors in the human pancreatic cancer cell lines CAPAN-1 and MIA PaCa-2 |
| Q30451017 | c-Kit-kinase induces a cascade of protein tyrosine phosphorylation in normal human melanocytes in response to mast cell growth factor and stimulates mitogen-activated protein kinase but is down-regulated in melanomas |
Search more.